Vancomycin covers nearly all gram-positive bacteria, including the major pathogens Staphylococcus, Streptococcus, Enterococcus, and Clostridioides difficile. It has no meaningful activity against gram-negative organisms. This makes it one of the most important antibiotics in medicine, often reserved as a last line of defense against resistant gram-positive infections.
How Vancomycin Works
Vancomycin kills bacteria by blocking cell wall construction. Gram-positive bacteria build their cell walls using a scaffolding material called peptidoglycan, and vancomycin latches onto the building blocks of that scaffold, specifically a small peptide chain that ends in two alanine molecules. When vancomycin binds to this target, the bacterium can no longer assemble its protective wall, and it dies.
This mechanism is highly effective against gram-positive bacteria because their peptidoglycan layer sits on the outside of the cell, fully exposed. Gram-negative bacteria, by contrast, have an additional outer membrane that acts as a physical barrier. Vancomycin is simply too large a molecule to pass through it, which is why it has no useful activity against organisms like E. coli, Pseudomonas, or Klebsiella.
Staphylococcus Coverage, Including MRSA
Vancomycin is one of the primary treatments for methicillin-resistant Staphylococcus aureus (MRSA), which resists most standard antibiotics. For serious MRSA infections like bloodstream infections, pneumonia, and bone infections, vancomycin remains a first-line option. The Infectious Diseases Society of America includes vancomycin prominently in its MRSA treatment guidelines, with specific recommendations for dosing and monitoring.
However, some S. aureus strains have developed reduced susceptibility to vancomycin. These fall into two categories: vancomycin-intermediate S. aureus (VISA), which requires higher concentrations to be killed, and vancomycin-resistant S. aureus (VRSA), which vancomycin cannot reliably treat at all. A global analysis found the overall prevalence of VISA at about 1.7% of tested strains, and VRSA at about 1.5%. Both have increased since 2010, with VISA prevalence rising roughly 3.6-fold compared to earlier years. These strains are still relatively uncommon, but their growing frequency is a real concern.
Streptococcus and Enterococcus
Vancomycin reliably covers Streptococcus species, including the groups responsible for skin infections, throat infections, and pneumonia. It serves as an alternative for patients who are allergic to penicillin or when resistant strains are involved.
Enterococcus is where vancomycin’s coverage gets more complicated. It works against most Enterococcus faecalis and Enterococcus faecium strains, but vancomycin-resistant enterococci (VRE) are a well-established problem, particularly in hospital settings. VRE strains carry genes (classified as vanA, vanB, and others) that modify the drug’s binding target. Instead of the normal two-alanine structure vancomycin recognizes, resistant bacteria swap in a slightly different molecule. This single change reduces vancomycin’s binding strength by roughly 1,000-fold. VanA-type VRE can tolerate vancomycin concentrations of 64 to over 1,000 micrograms per milliliter, far beyond what the drug can achieve in the body.
Because vancomycin alone is only bacteriostatic against enterococci (it stops growth but doesn’t reliably kill them), serious enterococcal infections like endocarditis typically require combining vancomycin with an aminoglycoside antibiotic to achieve true bacterial killing.
Clostridioides difficile
Vancomycin is a standard treatment for C. difficile infection, but with an important caveat: it must be given by mouth, not intravenously. When given through a vein, vancomycin does not reach high enough concentrations in the gut to kill C. difficile. Oral vancomycin, on the other hand, stays in the gastrointestinal tract where the infection lives. The typical course is 125 mg four times daily for 10 days. In more severe cases with complications like intestinal obstruction, higher doses may be used along with additional antibiotics.
Less Common Gram-Positive Pathogens
Beyond the major species, vancomycin covers several other gram-positive organisms that cause infections less frequently but can be difficult to treat with other drugs. Listeria monocytogenes, which causes serious foodborne illness especially in pregnant women and immunocompromised patients, shows good susceptibility to vancomycin. Corynebacterium species, some of which are highly resistant to other antibiotics, remain universally susceptible to vancomycin. In lab testing, all Corynebacterium strains studied were inhibited at very low vancomycin concentrations (1 microgram per milliliter or less), making it a reliable option for these infections when they arise.
What Vancomycin Does Not Cover
Vancomycin has no clinically useful activity against gram-negative bacteria. The outer membrane of gram-negative organisms physically blocks the drug from reaching its target. This means common infections caused by E. coli, Klebsiella, Pseudomonas, Acinetobacter, and similar organisms require entirely different antibiotic classes.
Among gram-positive organisms, the key gaps in coverage are VRE strains (particularly vanA-type) and the rare but growing population of VISA and VRSA S. aureus isolates. Vancomycin also has limited activity against certain Lactobacillus and Leuconostoc species, which are intrinsically resistant. These are uncommon causes of infection, but worth noting for the sake of completeness.
Why Monitoring Matters for Effectiveness
Vancomycin’s effectiveness depends heavily on maintaining the right drug levels in the blood. Current consensus guidelines recommend targeting a specific measure of drug exposure (the ratio of total drug exposure over 24 hours to the minimum concentration needed to inhibit the bacteria) between 400 and 600 for serious MRSA infections. Older practice relied on checking trough levels alone, but that approach has been phased out because it was associated with higher rates of kidney damage without improving outcomes. The shift to more precise monitoring reflects how narrow the window is between a dose that works and one that causes harm.